Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06504446
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-11
Brief Title:
Study to Assess the Efficacy Safety and Tolerability of NOC-110 in Adults with Refractory or Unexplained Chronic Cough
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2b Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Taplucainium Inhalation Powder NOC-110 in Adults with Refractory or Unexplained Chronic Cough
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ASPIRE
Brief Summary:
This is a phase 2b randomized double-blind placebo-controlled study investigating the efficacy safety and tolerability of Taplucainium Inhalation Powder NOC-110 once daily in adults with refractory or unexplained chronic cough
Detailed Description:
Approximately 325 participants will take part in the study It is anticipated that up to 600 participants will be screened Participation will be approximately 13 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None